NVSNovartis PharmaceuticalsRunning, no new patients
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 95 (final count)
- Started
- Dec 6, 2022
- Main results expected
- Nov 4, 2024
- Fully finished
- Oct 28, 2026
- Results posted
- Oct 9, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR) as Determined by the Investigator in Cohort A
Measured over: Up to approximately 22 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05445843 · record last updated 2026-10-08 · checked 2026-11-09 15:47 UTC